Continual administration of semaglutide led to 15% reduction in body weight at 68 weeks, along with improvements in cardiovascular risk and overall physiological condition [9]
Fanaroff, MD, JD (AA, Case Western Reserve, 1998) Gurleen Kaur Class of 2021, Albany Medical College Genetic modification of GREM1 to improve the efficacy of cardiac stem/progenitor cell therapy Mentor: Chuanxi Cai, PhD Councilor: Neil Lempert, MD (AA, Albany Medical College, 1978) Rohan Khazanchi Class of 2021, University of Nebraska College of Medicine Diagnostic utility and timing of routine head ultrasound screening in preterm infants Mentor: Eric Peeples, MD Councilor: Jason Shiffermiller, MD (AA, University of Nebraska, 1998) Connor Kinslow Class of 2019, Columbia University College of Physicians and Surgeons Targeting IDH1-Mutant Gliomas with Radiation Therapy and Glutamine Blockade Mentors: Simon Cheng, MD, PhD and Peter Canoll, MD, PhD Councilor: Timothy C
Adequate Sleep: Prioritize 7-9 hours of quality sleep per night
Metabolism & Elimination GLP2 undergoes metabolism through pathways typical of peptide therapeutics: Plasma half-life of approximately 5 days in humans, enabling once-weekly administration Primary metabolic pathways include proteolytic cleavage of the peptide backbone, beta-oxidation of the C20 fatty diacid moiety, and amide hydrolysis Not metabolized via cytochrome P450 enzymes, sulfation, or glucuronidation pathways Low potential for drug-drug interactions mediated through hepatic metabolism or transporter systems The extended half-life represents a key pharmacokinetic advantage, with steady-state accumulation of approximately 1.7-fold enabling consistent therapeutic exposure throughout the dosing interval
Post-procedure body treatment, like after laser treatments or certain surgeries, may involve copper peptides at concentrations determined by the treating practitioner
For self-injection, the upper arm presents a practical challenge